Twist Bioscience (NASDAQ:TWST) CFO Sells $384,810.60 in Stock

Posted by Stanley Muller on Oct 16th, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CFO Adam Laponis sold 2,462 shares of the business’s stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $156.30, for a total value of $384,810.60. Following the transaction, the chief financial officer directly owned 98,114 shares in the company, valued at $15,335,218.20. This trade represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Adam Laponis also recently made the following trade(s):

On Friday, October 2nd, Adam Laponis sold 8,057 shares of Twist Bioscience stock. The stock was sold at an average price of $188.88, for a total value of $1,521,806.16.

Twist Bioscience Stock Down 2.5%

Shares of NASDAQ:TWST opened at $144.49 on Friday. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $219.71. The company has a 50 day moving average of $147.75 and a two-hundred day moving average of $99.64. The company has a market capitalization of $9.06 billion, a price-to-earnings ratio of -65.09 and a beta of 2.19.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.33 EPS. As a group, analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Twist Bioscience in the second quarter worth $600,191,000. William Blair Investment Management LLC acquired a new stake in Twist Bioscience in the second quarter valued at $223,722,000. Bank of America Corp DE acquired a new stake in Twist Bioscience in the second quarter valued at $94,922,000. Allspring Global Investments Holdings LLC acquired a new stake in Twist Bioscience in the first quarter valued at $22,563,000. Finally, Sei Investments Co. raised its holdings in Twist Bioscience by 31.2% in the first quarter. Sei Investments Co. now owns 354,420 shares of the company’s stock valued at $16,842,000 after acquiring an additional 84,321 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Evercore lowered shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective on the stock. in a report on Monday, July 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Robert W. Baird raised their target price on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Guggenheim raised their target price on Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Finally, UBS Group began coverage on Twist Bioscience in a research report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $143.67.

Check Out Our Latest Report on TWST

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.